Strategic collaboration Planet Biotechnology has ongoing and past partnerships with iBio to develop COVID-19 therapeutics and ACE2-Fc immunoadhesin, signaling openness to co-development or licensing deals that can accelerate product timelines and broaden portfolio reach.

Plant-based platform appeal Their plant-made antibody platform (plantibodies) and rapid production in green plants highlight a differentiator for cost-efficient, scalable manufacturing that could attract customers seeking alternative bio-production methods.

Clinical trial activity History of clinical testing and active focus on infectious disease antibodies suggests potential for CDMO partnerships, joint ventures, or funded research collaborations around antiviral and outbreak-responsive therapies.

Niche market potential With a small team and revenue in the lower end of the spectrum, there may be opportunities for strategic customers looking to accelerate early-stage candidates through development stages via sponsored research, technology licensing, or pilot manufacturing.

Tech and IP leverage Experience in ACE2-Fc approaches and non-food plant production coupled with existing tech stack signals possible collaboration on scalable manufacturing processes, process development, and transfer of technology to client GMP facilities.